Anavex Life Sciences’ (AVXL) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a report released on Monday,Benzinga reports. The firm currently has a $24.00 price objective on the biotechnology company’s stock.

Other research analysts have also issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Anavex Life Sciences in a research report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Anavex Life Sciences in a research note on Monday, December 29th. Finally, Jones Trading lowered Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 24th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $22.00.

Anavex Life Sciences Price Performance

NASDAQ:AVXL opened at $3.88 on Monday. The firm’s 50-day moving average price is $4.28 and its 200-day moving average price is $6.95. The company has a market capitalization of $359.56 million, a PE ratio of -8.43 and a beta of 1.21. Anavex Life Sciences has a 1-year low of $2.86 and a 1-year high of $13.99.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.04. Equities analysts anticipate that Anavex Life Sciences will post -0.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Anavex Life Sciences

Institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. increased its holdings in Anavex Life Sciences by 187.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 872,968 shares of the biotechnology company’s stock worth $3,108,000 after buying an additional 569,579 shares in the last quarter. AXQ Capital LP boosted its holdings in shares of Anavex Life Sciences by 30.9% during the 4th quarter. AXQ Capital LP now owns 24,996 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 5,895 shares during the last quarter. Delta Asset Management LLC TN grew its stake in shares of Anavex Life Sciences by 23.1% in the fourth quarter. Delta Asset Management LLC TN now owns 16,000 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 3,000 shares during the period. Advisory Alpha LLC purchased a new position in shares of Anavex Life Sciences during the fourth quarter valued at approximately $44,000. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in shares of Anavex Life Sciences by 17,921.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 744,469 shares of the biotechnology company’s stock valued at $2,650,000 after purchasing an additional 740,338 shares during the last quarter. 31.55% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Anavex Life Sciences

Here are the key news stories impacting Anavex Life Sciences this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $20.00 price target (implying large upside) and published FY2027 and quarterly EPS forecasts that are less negative than consensus (FY2027 -$0.55 vs consensus -$0.69) — supportive for sentiment and valuation expectations. MarketBeat – AVXL HC Wainwright Report
• Positive Sentiment: Analysis pieces argue Anavex may be approaching cash‑flow breakeven, a narrative investors view positively for a small biotech with ongoing R&D spend. Breakeven On The Horizon For Anavex Life Sciences (Yahoo)
• Neutral Sentiment: The company’s Q1 2026 earnings call transcript is available for investors wanting primary detail on recent results and management commentary; it may clarify near‑term guidance but contains no single market‑moving surprise. Q1 2026 Earnings Call Transcript (MSN)
• Neutral Sentiment: Short‑interest reports show 0 shares and a days‑to‑cover of 0.0, but entries include NaN and appear to be data glitches — there is no clear evidence of new short pressure driving the move. (No linked source; reported in market data feed.)
• Negative Sentiment: A Seeking Alpha piece highlights a negative European regulator opinion on blarcamesine, Anavex’s lead asset, calling the program into “regulatory purgatory” — that regulatory uncertainty is the most direct near‑term negative for valuation and explains downward pressure. Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory (Seeking Alpha)

About Anavex Life Sciences

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.